A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non-Small-Cell Lung Cancer After Progression on Erlotinib

Am J Ther. 2023 Sep-Oct;30(5):e463-e465. doi: 10.1097/MJT.0000000000001598.
No abstract available

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • ErbB Receptors / genetics
  • Erlotinib Hydrochloride / therapeutic use
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Erlotinib Hydrochloride
  • osimertinib
  • ErbB Receptors
  • Protein Kinase Inhibitors
  • EGFR protein, human